
Wockhardt's Financial Results – Q2 (Jul-Sept) FY 2011-12**Wockhardt Sales up 18% and Operating Profit up 47%****Net Profit was ₹ 128 crore****Mumbai, November 12, 2011**

Pharmaceutical and Biotechnology major Wockhardt Limited today announced a 18% growth in consolidated sales revenues at ₹ 1,111 crore for the 2nd quarter ended 30th September 2011, over the corresponding quarter of 2010. Operating Profit (EBIDTA) was ₹ 323 crore, a growth of 47% and Net Profit was ₹ 128 crore.

“Wockhardt is showing consistent all-round growth globally. We are focussed on developing high-technology solutions like patented extended release products that will offer great value to all our stakeholders”, said Wockhardt Chairman Dr. Habil Khorakiwala. “Our commitment to the same can be seen from the fact that we received for the 3rd consecutive year, the Government of India Patents Award for the ‘Maximum Patents granted Worldwide to an Indian Company’, he further added.

USA Business:

Wockhardt USA showed a robust growth of 49% with its prime products improving market share in a highly competitive market scenario. There were 3 ANDA filings and 4 approvals for the quarter. For H1 (Apr-Sept 2011), Wockhardt USA received 8 approvals taking the overall tally to 84 approvals and Morton Grove Pharmaceuticals has 34 approvals till date. The infusion of new product launches will see Wockhardt USA breaking new ground in this market.

India Business:

Wockhardt's India business grew by 13.5% in the 2nd quarter, capturing a market share of 2.03% as compared to 1.94% last year (MAT Sept - IMS). In Q2-2011, 9 new products were launched. Also Wockhardt's 6 brands featured amongst the TOP-300 brands of the industry. The API business grew by 109% and Exports (RoW) grew by 32%. Wockhardt's Power Brands continue to push the boundaries of growth in the Indian Pharmaceutical market.

Europe Business:

Wockhardt UK continues to be the No.1 Indian generic company and overall the 4th generic company in the UK. Sales revenues grew by 3.6%. Wockhardt UK launched 3 new products and had 7 filings and 8 approvals during this period. Pinewood Healthcare continues to be the No.1 generic company in Ireland. It grew by 4.8% over the corresponding period of 2010-11, despite the industry showing de-growth of 4%. It also launched 2 new products in the Irish market during the said period with Nexazole achieving a 35% market share since its launch in June 2010.

About Wockhardt

Wockhardt is a high technology global pharmaceuticals and biotechnology major with innovative multi-disciplinary research and development programmes. It has 4 research centres and world-class manufacturing plants globally. Wockhardt has a multi-ethnic workforce of 6500 people from 14 different nationalities.

WOCKHARDT LIMITED

 Wockhardt Towers, Bandra-Kurla Complex
 Bandra (East), Mumbai 400 051, India

**UNAUDITED CONSOLIDATED FINANCIAL RESULTS
 FOR THE QUARTER ENDED 30TH SEPTEMBER, 2011**

(Rs. in Million)

PARTICULARS	QUARTER ENDED 30/09/2011	% TO SALES	QUARTER ENDED 30/09/2010	% TO SALES	GROWTH %	SIX MONTHS ENDED 30/09/2011	% TO SALES	SIX MONTHS ENDED 30/09/2010	% TO SALES	GROWTH %	YEAR ENDED 31/03/2011	% TO SALES
Income from Operations	11,105	100.0	9,401	100.0	18.1	21,637	100.0	18,617	100.0	16.2	37,512	100.0
Total Expenditure	7,872	70.9	7,203	76.6	9.3	15,295	70.7	14,616	78.5	4.6	28,425	75.8
a) (Increase)/Decrease in stock	(717)	(6.5)	370	3.9	(293.8)	(844)	(3.9)	406	2.2	(307.9)	617	1.6
b) Consumption of raw material	3,390	30.5	2,342	24.9	44.7	5,734	26.5	4,753	25.5	20.6	8,750	23.3
c) Purchase of Finished Goods	1,660	14.9	1,191	12.7	39.4	3,194	14.8	2,821	15.2	13.2	5,786	15.4
Material Consumption	4,333	39.0	3,903	41.5	11.0	8,084	37.4	7,980	42.9	1.3	15,153	40.4
d) Staff Cost	1,149	10.3	1,267	13.5	(9.3)	2,459	11.4	2,580	13.9	(4.7)	5,247	14.0
e) R & D expenditure	157	1.4	122	1.3	28.7	345	1.6	279	1.5	23.7	483	1.3
f) Other expenditure	2,233	20.1	1,911	20.3	16.8	4,407	20.4	3,777	20.3	16.7	7,542	20.1
Other Expenditure	3,539	31.9	3,300	35.1	7.2	7,211	33.3	6,636	35.6	8.7	13,272	35.4
Gross Profit before Interest, Depreciation & Taxation	3,233	29.1	2,198	23.4	47.1	6,342	29.3	4,001	21.5	58.5	9,087	24.2
Interest/ Financing Cost												
(a) Interest	398	3.6	565	6.0	(29.6)	983	4.5	1,209	6.5	(18.7)	2,671	7.1
(b) (Income)/Expense due to Exchange Rate Fluctuation	430		211			467		6			(1,366)	
Depreciation	280	2.5	299	3.2	(6.4)	660	3.1	594	3.2	11.1	1,166	3.1
Other Income	28	-	35	-	-	82	-	71	-	-	159	-
Profit/(Loss) Before Tax before exceptional items	2,153	19.4	1,158			4,314	19.9	2,263			6,775	18.1
Exceptional Item Profit/(Loss)	(681)		(2,020)			(681)		(4,176)			(5,732)	
Profit/(Loss) before Tax	1,472	13.3	(862)	(9.2)	270.8	3,633	16.8	(1,913)	(10.3)	289.9	1,043	2.8
Provision for Taxation	219		73			481		102			338	
Deferred Taxation	25		40			(21)		100			(252)	
Profit/(Loss) After Tax	1,228	11.1	(975)	(10.4)	225.9	3,173	14.7	(2,115)	(11.4)	250.0	957	2.6
Add: Share of Profit/(Loss) from Associates	47		8			42		(16)			(52)	
Net Profit/(Loss)	1,275	11.5	(967)	(10.3)	231.9	3,215	14.9	(2,131)	(11.4)	250.9	905	2.4
Paid-up Equity Share Capital (Rs 5/-each)	547		547			547		547			547	
Reserves excluding Revaluation Reserve (as per last audited Balance-Sheet)	-		-			-		-			1,251	
Earning Per Share												
Basic Earning Per Share (Rs)	11.66		(8.84)			29.38		(19.47)			8.27	
Diluted Earning Per Share (Rs)	11.66		(8.84)			29.38		(19.47)			8.27	

Public Shareholding							
- Number of Shares	28,421,193	28,275,055		28,421,193	28,275,055		28,392,021
- Percentage to Paid-up Capital	25.97%	25.84%		25.97%	25.84%		25.94%
Promoters and promoter group shareholding							
a) Pledged/ Encumbered							
- Number of shares	70,158,917	67,708,917		70,158,917	67,708,917		70,158,917
-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	87.06%	84.02%		87.06%	84.02%		87.06%
-Percentage of shares (as a % of the total share capital of the Company)	64.11%	61.87%		64.11%	61.87%		64.11%
b) Non-encumbered							
- Number of shares	10,426,465	12,876,465		10,426,465	12,876,465		10,426,465
-Percentage of shares (as a % of the total shareholding of promoter and promoter group)	12.94%	15.98%		12.94%	15.98%		12.94%
-Percentage of shares (as a % of the total share capital of the Company)	9.53%	11.77%		9.53%	11.77%		9.53%

Notes To Consolidated Financials:-

1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 12, 2011.

2) **Statement of Assets and Liabilities**

Particulars	(Rs. in Million)			
	As at 30/9/2011 (Unaudited)		As at 30/9/2010 (Unaudited)	
SHAREHOLDERS' FUNDS:				
(a) Capital	8,054		7,618	
(b) Reserves & Surplus	6,480	14,534	1,120	8,738
LOAN FUNDS		37,937		40,163
TOTAL		52,471		48,901
FIXED ASSETS		36,217		32,693
INVESTMENTS		938		932
DEFERRED TAX ASSET (NET)		823		371
CURRENT ASSETS, LOANS AND ADVANCES				
(a) Inventories	8,117		7,316	
(b) Sundry Debtors	7,523		6,153	
(c) Cash and bank Balances	5,339		3,690	
(d) Loans and Advances	2,499		3,551	
	23,478		20,710	
Less : Current Liabilities and Provisions				
(a) Liabilities	9,191		9,527	
(b) Provisions	1,144		384	
	10,335	13,143	9,911	10,799
MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)		0		0
PROFIT AND LOSS ACCOUNT		0		2,187
FOREIGN CURRENCY TRANSLATION RESERVE		1,350		1,919
TOTAL		52,471		48,901

3) Exceptional items for the quarter ended September 30, 2011 mainly comprises of settlement of loan/disputed derivative liabilities Rs. 777 million and reversal of excess provision for the restructuring cost in France Rs. 174 million.

4) During the quarter, Company has issued 10,921,071 Non Convertible Cumulative Redeemable Preference Shares (NCRPS) of Rs. 5/- each amounting to Rs. 54.61 million to various banks/financial institutions. The NCRPS are redeemable in the year 2018.

5) Against the pending petition, the Company has filed a consent decree in the Hon'ble High Court of Bombay and has agreed withdrawal by FCCB holders of Rs. 1,150 million deposited earlier and further agreed to pay balance FCCB outstanding along with interest on reducing balance, by August 2012. Further, the Hon'ble High Court of Bombay has permitted the divestment of Nutrition Business.

6) The Company has entered into definitive agreement on August 2, 2011 with Danone, for divestment of the Nutrition business. As the said transaction is subject to various closing conditions and approvals, the impact of this transaction will be accounted during the quarter in which the same is closed.

7) As on July 1, 2011 the Company had no investors complaints pending. During the quarter, the Company has not received any complaints. Accordingly, no complaints are pending as on September 30, 2011.

8) The Company is exclusively into Pharmaceutical business Segment.

9) Previous period figures have been recast/ re-classified to conform to the current period's presentation.